Diabetes and glucose disturbances in patients with psychosis in Sweden

BMJ Open Diabetes Research and Care

Volumn 3, Issue 1, 2015, Pages

  Olsson, Eric ^a,b   Westman, Jeanette ^a   Hukic, Dzana Sudic ^b,c   Eriksson, Sven V ^d   Edman, Gunnar ^a,b,c   Bodén, Robert ^a,e   Jedenius, Erik ^a   Reutfors, Johan ^a   Berntsson, Anders ^b   Hilding, Agneta ^a   Schalling, Martin ^a,c   Östenson, Claes Göran ^a   Ösby, Urban ^a,b,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b PRIMA Barn och Vuxenpsykiatri AB ^*  (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d DANDERYD HOSPITAL   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; QUESTIONNAIRE; SWEDEN; VERY ELDERLY; WAIST CIRCUMFERENCE;

EID: 85042573946     PISSN: None     EISSN: 20524897     Source Type: Journal    
DOI: 10.1136/bmjdrc-2015-000120     Document Type: Article

References (29)

1. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997;171:502-8.
2. Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000;45:21-8.
3. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007;64:1123-31.
4. Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA 2007;298:1794-6.
5. Osby U, Hammar N, Brandt L, et al. Time trends in first admissions for schizophrenia and paranoid psychosis in Stockholm County, Sweden. Schizophrenia Res 2001;47:247-54.
6. Crump C, Winkleby MA, Sundquist K, et al. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry 2013;170:324-33.
7. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
8. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32.
9. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(Suppl 1):1-93.
10. Osby U, Olsson E, Edman G, et al. Psychotic disorder is an independent risk factor for increased fasting glucose and waist circumference. Nord J Psychiatry 2014;68: 215-18.
11. Bushe C, Holt R. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry Suppl 2004;47:S67-71.
12. Merlotti C, Morabito A, Pontiroli AE. Prevention of type 2 diabetes; a systematic review and meta-analysis of different intervention strategies. Diabetes Obes Metab 2014;16:719-27.
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn. Text Revision. Washington DC: American Psychiatric Association, 2000.
14. Eriksson AK, Ekbom A, Granath F, et al. Psychological distress and risk of pre-diabetes and type 2 diabetes in a prospective study of Swedish middle-aged men and women. Diabet Med 2008;25:834-42.
15. Aas IH. Guidelines for rating Global Assessment of Functioning (GAF). Ann Gen Psychiatry 2011;10:2.
16. Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont) 2007;4:28-37.
17. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 2005;366:1059-62.
18. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006;23:469-80.
19. Eckel RH, Alberti KG, Grundy SM, et al. The metabolic syndrome. Lancet 2010;375:181-3.
20. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
21. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2007;30(Suppl 1):S42-7.
22. De Hert M, van Winkel R, Van Eyck D, et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health 2006;2:14.
23. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000;26:903-12.
24. De Hert MA, van Winkel R, Van Eyck D, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006;83:87-93.
25. Cheal KL, Abbasi F, Lamendola C, et al. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 2004;53:1195-200.
26. Knowler WC, Fowler SE, Hamman RF, et al; Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677-86.
27. Cahn A, Miccoli R, Dardano A, et al. New forms of insulin and insulin therapies for the treatment of type 2 diabetes. Lancet Diabetes Endocrinol 2015;3:638-52.
28. Sussman JB, Kent DM, Nelson JP, et al. Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program. BMJ 2015;350:h454.
29. Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008;299:185-93.